Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
about
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsHypoxia-independent drivers of melanoma angiogenesisRaf kinases in cancer-roles and therapeutic opportunitiesHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsHIF1α and HIF2α independently activate SRC to promote melanoma metastasesHypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progressionPersonalising and targeting antiangiogenic resistance: a complex and multifactorial approach.Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin.Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanomaMolecular bases of cutaneous and uveal melanomas.Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancerSnail1 mediates hypoxia-induced melanoma progressionTargeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway.Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation.Role of chemokines in tumor growth.The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growthIdentification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma developmentThe combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expressionHIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformationUnderstanding signaling cascades in melanomaDysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4mTOR pathway in renal cell carcinoma.The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytesTargeting the hypoxia-inducible factor (HIF) pathway in cancer.MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma.Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.Putative role of HIF transcriptional activity in melanocytes and melanoma biology.The potential role of HIF on tumour progression and dissemination.Loss of microRNA-205 expression is associated with melanoma progression.Acidic tumor microenvironment in human melanoma.Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy.MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.
P2860
Q26747247-84DBBC2E-DE8B-4A8D-A2BC-B8A1A03C5F4BQ26862544-5F120189-E245-486C-9B3C-F8B4A0CDE9A8Q27022246-05752ADE-72AF-4D83-838D-A5E4BF191971Q28237793-512E2D9D-3D58-4304-8D18-4FED26DE2897Q28393898-8D892A29-BCE3-45B2-8DC7-11789230F4FFQ30539170-9F34A635-F5AD-441E-8B27-1B03B2C9FC00Q33382510-D19858A6-00AD-43E1-AFB5-286B303F5E8FQ33639714-0EE8DF4E-EE13-4844-BF7F-839024C5017DQ33725172-5C4F223D-A731-4D8B-AFA3-E247B6C87024Q34570988-62EA8988-AAB4-422B-B1EC-C6241FE189BDQ34975272-C403FEB6-1DA5-499C-B4E9-582DF7E9C85EQ35174214-6018F07C-14E4-4473-B9CF-15CBADF7102FQ35677725-414E0B8D-B1DB-4AA1-BA9A-282EE65B2047Q35679320-1A11F235-D6FB-42F6-A5CE-259FA8186AF2Q35751013-DA5D6ADC-791A-430A-98D1-7B5E2CD0D56EQ35760949-ED6742AD-D117-438B-9085-A0F941CA18D3Q35931312-5B1B7F5B-5D53-4FA5-BEE4-E0576FF6074AQ36120825-E0AA6A8D-D306-4809-A2AA-A5CE651898A2Q36545304-2824FDC8-39E8-4B90-A106-2A6614C3D2FBQ36666379-CCA3259C-61B5-43B3-9996-63AB3058ECE3Q36684583-4E58BC82-861A-4B22-A1BF-3DB67E716DF8Q36822204-2F525E95-3C89-41EF-8FAA-F7F250C6D35AQ36961667-188D6B6B-0A78-4F9F-805A-A27F296B83BFQ37034487-AF64383A-84E4-480A-B2FB-165F9A64AC3CQ37038401-8C3DFC19-6ABF-4953-80E0-7493BEEE9495Q37068082-B938C63D-BCE7-4F34-9346-3B419CA4D4C8Q37086022-6F5CF70B-6850-43D7-AE12-409D6FB61F3CQ37197419-0FE960E4-10F1-4A88-8799-7A775578977DQ37587446-E79AE780-B1AB-4EF4-81D4-7B4409EAED80Q37646533-B30A73A5-25B3-487B-B3C1-5B1083FAD165Q38107793-33E2B533-FD45-470B-A579-1DDAC9DB2045Q38108833-B8585D8B-5E40-4D8F-991E-D47160F230E9Q38160223-43F1D7C1-FF14-4DFB-BB94-C323F54E973CQ38204343-8ED10FC6-BEDA-4159-8847-B2574732C020Q38325937-0D3E7821-E9DA-4EC5-8949-FE04C5161892Q38846154-8A81B17A-DF42-4152-A3D5-7224F24F00BDQ38872439-63B30EE3-BCFE-4DC0-9EEE-AA6F6CB97135Q38874710-D29A5527-6F20-41AE-88EA-C555038E508BQ38970551-00D9AAA6-0BEB-400E-8AA9-F5B52CE33AE5Q39277922-13ABE42D-D5E3-4018-8065-31D603A558D9
P2860
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
@en
type
label
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
@en
prefLabel
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
@en
P2093
P1433
P1476
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
@en
P2093
Lianjun Chen
Patricia Brafford
Robin Edwards
Steven Kazianis
Suresh M Kumar
Xiaowei Xu
P304
P356
10.1158/0008-5472.CAN-06-3312
P407
P577
2007-04-01T00:00:00Z